Nang Kuang Pharmaceutical Co (1752) Fair Value & Analysis
Healthcare · TW · Market cap 3.3B TWD
Fair value as of: Jun 24, 2026
Analysis
Nang Kuang Pharmaceutical Co (1752) currently trades at 32.75 TWD, while our model-based Fair Value estimate is 44.52 TWD — implying the stock looks roughly 35.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Nang Kuang Pharmaceutical Co., Ltd. manufactures, processes, trades in, imports, and exports pharmaceuticals and medical devices in Taiwan, China, Japan, the United States, and internationally. The company offers ready to use injections, such as prefilled syringe injections and premixed IV infusions; anti-aging and preventive medicines; chemotherapy and oncology products; and non-PVC IV infusion. It also provides various products in the areas of cardiovascular, gastrointestinal, nervous, musculo-skeletal, and respiratory system, as well as in alimentary and metabolism, blood, antineoplastic and immunomodulatory, dermatological, genito-urinary and sex hormone, systemic hormone and antibacterial, cosmetics, and hospital solutions. In addition, the company is involved in trading of pharmaceuticals. Nang Kuang Pharmaceutical Co., Ltd. was founded in 1963 and is headquartered in Tainan City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Nang Kuang Pharmaceutical Co (1752) undervalued?
What is the fair value of 1752?
What is the quality score of 1752?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.